These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16018740)

  • 1. The role of adjuvants in the development of mucosal vaccines.
    Vajdy M; Singh M
    Expert Opin Biol Ther; 2005 Jul; 5(7):953-65. PubMed ID: 16018740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Harandi AM; Czerkinsky C
    Expert Rev Vaccines; 2003 Apr; 2(2):205-17. PubMed ID: 12899572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.
    Pizza M; Giuliani MM; Fontana MR; Monaci E; Douce G; Dougan G; Mills KH; Rappuoli R; Del Giudice G
    Vaccine; 2001 Mar; 19(17-19):2534-41. PubMed ID: 11257389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal delivery of vaccines.
    Del Giudice G; Pizza M; Rappuoli R
    Methods; 1999 Sep; 19(1):148-55. PubMed ID: 10525451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants.
    Bagley KC; Abdelwahab SF; Tuskan RG; Lewis GK
    Infect Immun; 2003 Dec; 71(12):6850-6. PubMed ID: 14638772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the activity of mucosal adjuvants.
    Baudner BC; Giudice GD
    Methods Mol Biol; 2010; 626():261-85. PubMed ID: 20099134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines: the future of intranasal vaccine adjuvants.
    Thompson AL; Staats HF
    Clin Dev Immunol; 2011; 2011():289597. PubMed ID: 21826181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation using bacterial enterotoxins.
    Simmons CP; Ghaem-Magami M; Petrovska L; Lopes L; Chain BM; Williams NA; Dougan G
    Scand J Immunol; 2001 Mar; 53(3):218-26. PubMed ID: 11251877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal vaccine design and delivery.
    Woodrow KA; Bennett KM; Lo DD
    Annu Rev Biomed Eng; 2012; 14():17-46. PubMed ID: 22524387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
    Yamamoto M; McGhee JR; Hagiwara Y; Otake S; Kiyono H
    Scand J Immunol; 2001 Mar; 53(3):211-7. PubMed ID: 11251876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in mucosal vaccines and adjuvants.
    Eriksson K; Holmgren J
    Curr Opin Immunol; 2002 Oct; 14(5):666-72. PubMed ID: 12183170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity.
    Enioutina EY; Visic D; Daynes RA
    Vaccine; 2000 Jun; 18(24):2753-67. PubMed ID: 10781863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and maintenance of mucosal memory B cell responses?
    Vajdy M
    Curr Med Chem; 2006; 13(25):3023-37. PubMed ID: 17073644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterial toxins as mucosal adjuvants.
    Freytag LC; Clements JD
    Curr Top Microbiol Immunol; 1999; 236():215-36. PubMed ID: 9893362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins.
    Lycke N; Bemark M
    Mucosal Immunol; 2010 Nov; 3(6):556-66. PubMed ID: 20844480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel vaccine development strategies for inducing mucosal immunity.
    Fujkuyama Y; Tokuhara D; Kataoka K; Gilbert RS; McGhee JR; Yuki Y; Kiyono H; Fujihashi K
    Expert Rev Vaccines; 2012 Mar; 11(3):367-79. PubMed ID: 22380827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of plant-derived vaccine antigens to immunoresponsive mucosal sites.
    Rigano MM; Sala F; Arntzen CJ; Walmsley AM
    Vaccine; 2003 Jan; 21(7-8):809-11. PubMed ID: 12531365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
    Lawson LB; Norton EB; Clements JD
    Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal Vaccine Development Based on Liposome Technology.
    Bernasconi V; Norling K; Bally M; Höök F; Lycke NY
    J Immunol Res; 2016; 2016():5482087. PubMed ID: 28127567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.